Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL778096 | 0.84 | CA1 (0.42) | CA1CA2CA9ALDH1A1 | |
| Formaldehyde SCHEMBL27924107 | 0.79 | CA1 (0.39) | CA1CA2CA9ALDH1A1 | |
| SCHEMBL10896761 | 0.77 | CA1 (0.37) | CA1CA2CA9ALDH1A1 | |
| SCHEMBL4611124 | 0.75 | CA1 (0.41) | CA1CA2CA9ALDH1A1 | |
| SCHEMBL964195 | 0.74 | — | — | |
| Formaldehyde SCHEMBL27821465 | 0.73 | CA1 (0.34) | CA1CA2CA9ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL9528500 | 0.73 | CA1 (0.39) | CA1CA2CA9ALDH1A1 | |
| Methyl Alcohol SCHEMBL10924123 | 0.71 | CA1 (0.33) | CA1CA2CA9ALDH1A1 | |
| SCHEMBL776575 | 0.70 | — | — | |
| SCHEMBL3877626 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023126978-A1 | PROCESS TO PREPARE OCTOPAMINE SULFATE | DIRECTOR, NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH, GUWAHATI (NIPER-G) (IN) | 2023-07-06 | — | — | WO | disclosed |
| US-20150368204-A1 | Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity | Salix Pharmaceuticals, Ltd | 2015-12-24 | — | — | US | disclosed |
| US-20150011564-A1 | Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity | SPROUT PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8722682-B2 | Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity | SPROUT PHARMACEUTICALS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2097389-B1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | BOEHRINGER INGELHEIM INT (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20110015207-A1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2097389-A1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | Boehringer Ingelheim International GmbH (DE) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008074795-A1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011564-A1 | Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity | HTR3B, HTR3A, HTR1E | CA1 3662/4885CA2 3759/4885CA9 4815/4885 |
| US-20150368204-A1 | Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity | HTR3B, HTR3A, HTR1E | CA1 3669/4885CA2 3826/4885CA9 4826/4885 |
| US-20110015207-A1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | HTR3A, HTR3B, NPSR1 | CA1 3824/4885CA2 3341/4885CA9 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.